CN1413655A - Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method - Google Patents

Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method Download PDF

Info

Publication number
CN1413655A
CN1413655A CN 02131434 CN02131434A CN1413655A CN 1413655 A CN1413655 A CN 1413655A CN 02131434 CN02131434 CN 02131434 CN 02131434 A CN02131434 A CN 02131434A CN 1413655 A CN1413655 A CN 1413655A
Authority
CN
China
Prior art keywords
ethanol
extract
parts
supernatant
centrifugal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 02131434
Other languages
Chinese (zh)
Other versions
CN1254252C (en
Inventor
刘建勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 02131434 priority Critical patent/CN1254252C/en
Publication of CN1413655A publication Critical patent/CN1413655A/en
Application granted granted Critical
Publication of CN1254252C publication Critical patent/CN1254252C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A Chinese medicine for treating ischemic cardiovascular and cerebrovascular diseases is prepared from 3 Chinese-medicinal materials ginseng, red sage root and corydalis tuber through extracting, separating by adsorptive resin, eluting and concentrating. Its advantages are high curative effect and low cost.

Description

A kind of medicine and manufacture method thereof that is used for the treatment of ischemic cerebrocardiac disease
Technical field
The present invention is a kind of Chinese patent medicine for the treatment of ischemic cerebrocardiac disease, be specifically a kind of be the Chinese patent medicine that active component is prepared from the natural plant, belong to field of traditional Chinese.
Background technology
In the prior art, the medicine that is used for the treatment of ischemic cardio cerebrovascular diseases is a lot, for example: treating coronary heart disease capsule, DIAOXINXUE KANG, XINNAOKANG JIAONANG, FUFANG DANSHEN DIWAN etc.But the number of the infected of ischemic cardio cerebrovascular diseases is numerous, and pathogeny is varied, and existing medicine still can not satisfy clinical needs, thereby needs a kind of high-efficiency low-toxicity medicine of invention to satisfy clinician and patient's needs.
Summary of the invention
The object of the invention provides a kind ofly has fine therapeutical effect, nontoxic modern Chinese medicine to ischemic cerebrocardiac disease.
Another object of the present invention provides a kind of preparation technology who treats the ischemic cerebrocardiac disease medicine.
According to the principles of formulating prescriptions of theory of Chinese medical science,, determine the raw material prescription of preparation medicine of the present invention according to secular clinical practice.
Said pharmaceutical composition with the effect of treatment ischemic cerebrocardiac disease contains the Chinese medicine of following weight ratio among the present invention:
Radix Ginseng 2-50 part Radix Salviae Miltiorrhizae 1-20 part Rhizoma Corydalis 10-100 part.
The preferred proportioning of material medicine of the present invention is
15~80 parts of 1~15 part of Rhizoma Corydalis of 2~30 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
The further preferred proportioning of material medicine of the present invention is
Radix Ginseng 2-20 part Radix Salviae Miltiorrhizae 1-10 part Rhizoma Corydalis 20-50 part.
Material medicine of the present invention also contains material medicine Flos Carthami 5-40 part.
The Chinese medicine optimum weight ratio of pharmaceutical composition of the present invention is:
25 parts of 2 parts of Rhizoma Corydalis of 4 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
The optimum weight ratio of the Chinese medicine extract of pharmaceutical composition of the present invention is:
10 parts of Radix Ginseng extracts
10 parts of Radix Salviae Miltiorrhizae extracts
24 parts of Rhizoma Corydalis extracts
The Flos Carthami extract that can also further contain 5 weight portions.
The said dosage form of the present invention comprises any dosage form in liquid preparation, solid preparation, semi-solid preparation and the gas preparation.
Said oral liquid, suspension, syrup, injection, medicated wine, the tincture etc. of comprising of the present invention
The said solid of the present invention, semi-solid preparation comprise tablet, pill, unguentum, sublimed preparation, powder, granule, suppository, powder, masticatory, capsule etc.
The said gas preparation of the present invention comprises aerosol, inhalant etc.
The preferred dosage form of medicine of the present invention is a capsule, and this has directly related property with the preparation technology of medicine of the present invention.
Specific embodiment medicine of the present invention is to be prepared from according to following preparation technology:
Select material medicine Radix Ginseng 2-50 part Radix Salviae Miltiorrhizae 1-20 part Rhizoma Corydalis 10-100 part.
Radix Ginseng is pulverized, and 5~20 times of amounts of ethanol extract twice, merge extractive liquid,, concentrating under reduced pressure, remove ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract a; Radix Salviae Miltiorrhizae is extracted 3 times with 5~10 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to the solution of 1~4 times of amount volume, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract b; Rhizoma Corydalis is pulverized, and 5~15 times of amounts of ethanol are extracted merge extractive liquid,, concentrating under reduced pressure 3 times, remove ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract c; Mix a, b, three kinds of extracts of c, be prepared into medicament with the pharmaceutical technology of routine, promptly.
The further embodiment of the present invention is as follows: Radix Ginseng is pulverized, extract twice with 10 times of amounts of 60% ethanol, each extraction time is 1~2 hour, the merge extractive liquid, concentrating under reduced pressure, remove ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a.Radix Salviae Miltiorrhizae is extracted 3 times with 8 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to 3 times of solution of measuring volumes to be, centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract b.Rhizoma Corydalis is pulverized, extracted 3 times with 8 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c.
Get said extracted thing a, b, c weight ratio 9~11: 9~11: 23~25, add lactose, microcrystalline Cellulose, pre-colloidality Starch Sodium, mix homogeneously is crossed 40 mesh sieves, incapsulates, and its content weight is 125mg, promptly.
When also comprising the Flos Carthami extract of 5 weight ratios, described Flos Carthami extract is prepared as follows: Flos Carthami adds the ethanol merceration, filter, medicinal residues add the ethanol merceration again, filter, merge lixivium twice, be evaporated to and add entry, last adsorbent resin, the medicine carrying resin is earlier with distilled water flushing, wash post with ethanol again, ethanol elution is concentrated into does promptly.
Pharmacodynamic study proves that this medicine has following pharmacologically active:
1. experiment adopts ligation dog coronary artery method to cause myocardial infarction and ischemia model, give this medicine through duodenum, this medical instrument effect of dog acute myocardial ischemia and myocardial infarction that has clear improvement as a result alleviates by the degree of myocardial ischemia of epicardial electrogram mapping (∑-ST) and myocardial ischemia scope (N-ST); Obviously reduce through the shown infarct of N-BT dyeing; Significantly suppress the active rising of serum creatine phosphokinase (CK) that myocardial ischemia and myocardial infarction cause, and the release of lactic acid dehydrogenase (LDH) is had inhibitory action; Reduce blood plasma ET and TXB 2Level improves the 6-Keto-PGFl alpha active, increases 6-Keto-PGFl α/TXB 2Ratio.
Experiment adopt ligation again method for filling cause the rat myocardial ischemia and reperfusion damage model; give this medicine through duodenum; the result shows that this medicine can alleviate rat myocardial ischemia and reperfusion myocardial damage degree; obviously dwindle myocardial infarction area; alleviate infarct weight; and can obviously reduce serum paraoxonase creatine phosphate kinase (CK) content and malonaldehyde (MDA) content, and obviously increase serum superoxide dismutases (SOD) activity, myocardial ischemia reperfusion injury there is significant protective effect.
3. the influence experiment to open chest anesthetized cardiac hemodynamics of dogs and myocardial oxygen consumption shows, this medicine is dilating coronary blood vessel obviously, reduce coronary resistance and myocardial oxygen consumption, remarkable coronary blood flow increasing and crown venous sinus oxygen content, thereby improve the blood supply oxygen supply of cardiac muscle, adjust cardiovascular compliance, cardiovascular system is played adjust and the improvement effect.
4. adopt the BornShi turbidimetry, observe of the influence of the logical hat of Radix Triplostegiae Grandiflorae capsule the rabbit platelet aggregation.The result shows: continuous 7 days gastric infusions, this medicine can obviously reduce arachidonic acid (AA), adenosine diphosphate (ADP) (ADP) and collagen-induced rabbit platelet aggregation rate.The logical hat of prompting Radix Triplostegiae Grandiflorae capsule has the effect of anticoagulant.
5. the experimental result to rats in vitro thrombosis and blood viscosity influence shows that continuous 7 days gastric infusions, this medicine can obviously shorten thrombosis length, alleviate wet weight of thrombus and dry weight, reduces whole blood viscosity and plasma viscosity.Point out this medical instrument that the thrombotic effect of inhibition is arranged.
6. experiment causes the focal cerebral ischemia model with electrocoagulation blocking-up rat brain medium-sized artery, and duodenal administration is observed the therapeutical effect of this medicine to focal cerebral ischemia.The result shows, this medicine is respectively organized the rat focus of infarct all dwindling in various degree, and the neurobehavioral obstacle of animal obviously alleviates behind the cerebral infarction, animal serum SOD is active obviously to be increased, Content of MDA is not seen obvious change, and blood plasma ET content obviously reduces, and cerebral index is not seen significant change.This medicine of results suggest has therapeutical effect to focal cerebral ischemia.
7. with the ligation bilateral common carotid arteries and discharge the blood voltage drop method, cause rat imperfection cerebral ischemic model, observe of the influence of this medicine the imperfection cerebral ischemia.The result shows that this medicine has significant protective effect to active reduction of brain water content increase, cerebral tissue SOD due to the cerebral ischemia, illustrates that this medicine has protective effect to cerebral ischemia.
8. cause the chmice acute cerebral ischemic model with head-breaking, observe the resisting oxygen lack of medicine.The result shows that after the filling stomach gave this medicine, the mouse breathing number of times obviously increased, and breathing time obviously prolongs, and points out this medicine that acute cerebral ischemia is had protective effect.
9. experiment is main observation index with the ICAF amount, observes the influence of this medicine to the anesthetized dog cerebral blood flow.The result shows that this medicine is the cerebral blood flow increasing amount significantly, reduces cerebral vascular resistance; Arteriotony, heart rate, electrocardiogram there is not obvious influence.
Advantage of the present invention is to extract each active component respectively from Radix Ginseng, Radix Salviae Miltiorrhizae and Rhizoma Corydalis, makes medicament against cardiovascular disease with optimal proportion, activity that not only can each single active component of centralized displaying, and also can improve the activity of each component by compatibility.Meanwhile,, adopt better simply manufacturing process again, reduced production cost, help practical application owing to being raw material with resource plant rich and easy to get.
Embodiment 1
Radix Ginseng 4kg Radix Salviae Miltiorrhizae 2kg
Rhizoma Corydalis 25kg
Radix Ginseng is pulverized, extracted twice with 5~20 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a.Radix Salviae Miltiorrhizae is extracted 3 times with 5~10 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to the solution of 1~4 times of amount volume, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract b.Rhizoma Corydalis is pulverized, extracted 3 times with 5~15 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c, pharmaceutical technology with routine is prepared into medicament, promptly.
Embodiment 2
Radix Ginseng is pulverized, extracted twice with 5~20 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a.Radix Salviae Miltiorrhizae is extracted 3 times with 5~10 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to the solution of 1~4 times of amount volume, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract b.Rhizoma Corydalis is pulverized, extracted 3 times with 5~15 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c.
Got said extracted thing a, b, c weight ratio 10: 10: 24, and added lactose, microcrystalline Cellulose, pre-colloidality Starch Sodium, its weight is respectively 1/4,1/4,1/16 of extract mixtures weight, mix homogeneously, mix homogeneously is crossed 40 mesh sieves, incapsulate, its content weight is 125mg, promptly.When the clinical drug of gained uses three times on the one, one time 1~4, medicining times and consumption can be added and subtracted with doctor's advice.
When also containing Flos Carthami extract, described Flos Carthami extract is prepared as follows: Flos Carthami adds the ethanol merceration, filters, and medicinal residues add the ethanol merceration again, filter, merge lixivium twice, be evaporated to and add entry, last adsorbent resin, the medicine carrying resin is earlier with distilled water flushing, wash post with ethanol again, ethanol elution is concentrated into does promptly, select in the mixture after the Flos Carthami extract of 5 weight ratios is sneaked into aforesaid extraction.
Embodiment 3
Radix Ginseng 4kg
Radix Salviae Miltiorrhizae 2kg
Rhizoma Corydalis 25kg
Radix Ginseng is pulverized, extracted twice with 10 times of amounts of 60% ethanol, each extraction time is 2 hours, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a.Radix Salviae Miltiorrhizae is extracted 3 times with 8 times of water gagings, and each extraction time is 60 minutes, is evaporated to 3 times of solution of measuring volumes to be, centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract b.Rhizoma Corydalis is pulverized, extracted 3 times with 8 times of amounts of 60% ethanol, each extraction time is 2 hours, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c.
Got said extracted thing a, b, c weight ratio 10: 10: 24, and added lactose, microcrystalline Cellulose, pre-colloidality Starch Sodium, its weight is respectively 1/4,1/4,1/16 of extract mixtures weight, mix homogeneously, mix homogeneously is crossed 40 mesh sieves, incapsulate, its content weight is 125mg, promptly.
Embodiment 5
Radix Ginseng 20kg Radix Salviae Miltiorrhizae 10kg
Rhizoma Corydalis 50kg
Radix Ginseng is pulverized, extracted twice with 5~20 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a.Radix Salviae Miltiorrhizae is extracted 3 times with 5~10 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to the solution of 1~4 times of amount volume, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract b.Rhizoma Corydalis is pulverized, extracted 3 times with 5~15 times of amounts of 60% ethanol, each extraction time is 1~2 hour, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c, pharmaceutical technology with routine is prepared into medicament, promptly.
Embodiment 6
Choose
Radix Ginseng 30kg
Radix Salviae Miltiorrhizae 15kg
Rhizoma Corydalis 80kg
All the other are with embodiment 5.

Claims (10)

1. pharmaceutical composition for the treatment of ischemic cerebrocardiac disease is characterized in that it contains the material medicine of following weight ratio:
10~100 parts of 1~20 part of Rhizoma Corydalis of 2~50 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
2. according to the pharmaceutical composition of claim 1, it is characterized in that the weight ratio of each component is:
15~80 parts of 1~15 part of Rhizoma Corydalis of 2~30 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
3. according to the pharmaceutical composition of claim 2, it is characterized in that the weight ratio of each component is:
20~50 parts of 1~10 part of Rhizoma Corydalis of 2~20 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
4. according to the pharmaceutical composition of claim 3, it is characterized in that the weight ratio of each component is:
25 parts of 2 parts of Rhizoma Corydalis of 4 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng.
5. the pharmaceutical composition of claim 1 is characterized in that it also contains 5~40 parts on material medicine Flos Carthami.
6. the pharmaceutical composition in the claim 1~5, its dosage form is selected from any in liquid preparation, solid preparation, semi-solid preparation and the gas preparation, said liquid preparation comprises oral liquid, suspension, syrup, injection, medicated wine and tincture, said solid and semi-solid preparation comprise tablet, pill, unguentum, sublimed preparation, powder, granule, suppository, powder, Emulsion, masticatory and capsule, and said gas preparation comprises aerosol, inhalant.
7. the preparation of drug combination method of claim 1 is characterized in that:
Selection is according to the materials of weight proportions medicine of claim 1;
Radix Ginseng is pulverized, and 5~20 times of amounts of ethanol extract twice, merge extractive liquid,, concentrating under reduced pressure, remove ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract a; Radix Salviae Miltiorrhizae is extracted 3 times with 5~10 times of water gagings, and each extraction time is 30~60 minutes, is evaporated to the solution of 1~4 times of amount volume, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract b; Rhizoma Corydalis is pulverized, and 5~15 times of amounts of ethanol are extracted merge extractive liquid,, concentrating under reduced pressure 3 times, remove ethanol, be concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract c; Mix a, b, three kinds of extracts of c, be prepared into medicament with the pharmaceutical technology of routine, promptly.
8. according to the method for preparing extractive of claim 7, it is characterized in that method for making is:
Choose 25 parts of 2 parts of Rhizoma Corydalis of 4 parts of Radix Salviae Miltiorrhizaes of Radix Ginseng; Radix Ginseng is pulverized, and 10 times of amounts of ethanol extract twice, and each extraction time is 2 hours, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract a; Radix Salviae Miltiorrhizae is extracted 3 times with 8 times of water gagings, and each extraction time is 60 minutes, is evaporated to 3 times of solution of measuring volumes to be, centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract b; Rhizoma Corydalis is pulverized, extracted 3 times with 8 times of amounts of 60% ethanol, each extraction time is 100022 hours, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, is concentrated into room temperature relative density 1.05~1.15, centrifugal, precipitation discards, with supernatant with the adsorbent resin separation and concentration, with rare pure eluting, collect eluent, concentrate drying gets extract c; Get said extracted thing a, b, c weight ratio 9~11: 9~11: 23~24, add lactose, microcrystalline Cellulose, pre-colloidality Starch Sodium, mix homogeneously is crossed 40 mesh sieves, incapsulates, and its content weight is 125mg, promptly.
9, a kind of pharmaceutical composition for the treatment of ischemic cerebrocardiac disease is characterized in that it comprises following components in part by weight:
Radix Ginseng extract 9~11, Radix Salviae Miltiorrhizae extract 9~11, Rhizoma Corydalis extract 23~25;
Described Radix Ginseng extract is prepared as follows: Radix Ginseng pulverized, and ethanol extraction, merge extractive liquid,, concentrating under reduced pressure is removed ethanol, and centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract; Described Radix Salviae Miltiorrhizae extract is prepared as follows: with the Radix Salviae Miltiorrhizae water extraction, and concentrating under reduced pressure, centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract; Described Rhizoma Corydalis extract is prepared as follows: Rhizoma Corydalis pulverized, used ethanol extraction, and merge extractive liquid,, concentrating under reduced pressure is removed ethanol, and centrifugal, precipitation discards, and supernatant with the adsorbent resin separation and concentration, with rare pure eluting, is collected eluent, and concentrate drying gets extract.
10, the pharmaceutical composition of claim 9, it is characterized in that it also comprises the Flos Carthami extract of 4~6 weight ratios, described Flos Carthami extract is prepared as follows: Flos Carthami adds the ethanol merceration, filters, medicinal residues add the ethanol merceration again, filtration merges lixivium twice, is evaporated to add entry, last adsorbent resin, the medicine carrying resin is washed post with ethanol more earlier with distilled water flushing, ethanol elution is concentrated into does promptly.
CN 02131434 2002-10-14 2002-10-14 Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method Expired - Lifetime CN1254252C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02131434 CN1254252C (en) 2002-10-14 2002-10-14 Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02131434 CN1254252C (en) 2002-10-14 2002-10-14 Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method

Publications (2)

Publication Number Publication Date
CN1413655A true CN1413655A (en) 2003-04-30
CN1254252C CN1254252C (en) 2006-05-03

Family

ID=4746680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02131434 Expired - Lifetime CN1254252C (en) 2002-10-14 2002-10-14 Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method

Country Status (1)

Country Link
CN (1) CN1254252C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284050B (en) * 2008-05-09 2011-02-16 浙江现代中药与天然药物研究院有限公司 Corydalis tuber water soluble part medicament and its preparation method and application
CN102228493A (en) * 2011-06-27 2011-11-02 北京大学第一医院 Medicine for treating coronary heart disease
CN106265862A (en) * 2016-08-23 2017-01-04 上海市中西医结合医院 The medical usage of Semen arachidis hypogaeae branch and leaf decocting liquid
CN114712475A (en) * 2022-05-10 2022-07-08 云南中医药大学 Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia
CN116747257A (en) * 2023-06-28 2023-09-15 中国中医科学院西苑医院 Traditional Chinese medicine composition for treating or preventing cardiac insufficiency or heart failure

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284050B (en) * 2008-05-09 2011-02-16 浙江现代中药与天然药物研究院有限公司 Corydalis tuber water soluble part medicament and its preparation method and application
CN102228493A (en) * 2011-06-27 2011-11-02 北京大学第一医院 Medicine for treating coronary heart disease
CN106265862A (en) * 2016-08-23 2017-01-04 上海市中西医结合医院 The medical usage of Semen arachidis hypogaeae branch and leaf decocting liquid
CN114712475A (en) * 2022-05-10 2022-07-08 云南中医药大学 Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia
CN114712475B (en) * 2022-05-10 2023-06-16 云南中医药大学 Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof
CN116747257A (en) * 2023-06-28 2023-09-15 中国中医科学院西苑医院 Traditional Chinese medicine composition for treating or preventing cardiac insufficiency or heart failure

Also Published As

Publication number Publication date
CN1254252C (en) 2006-05-03

Similar Documents

Publication Publication Date Title
CN100345558C (en) Extract product of general flavone of kudzuvine root, preparation method and application
CN1824177A (en) Medicinal composition for treating hypertension, its preparation method and use
CN1254252C (en) Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method
CN1923227A (en) Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof
CN1304769A (en) Blood-cleaning pill
CN101234170A (en) Sanweishengmai injection and preparation thereof
CN1272026C (en) Medicinal composition for treating cardiocerebral vasculr disease and its preparing method
CN1853688A (en) Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof
CN1316992C (en) Medicine for treating heart brain embulus disease and its preparation method
CN1228332A (en) Drug for curing migraine and its preparing method
CN1182862C (en) Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn
CN1296087C (en) Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof
CN1425379A (en) Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method
CN1242801C (en) Medicinal composition for treating coronary heart disease and angine pectoris
CN1939390A (en) Medicinal composition and its making method
CN1682972A (en) Chinese medicine composition for treating cardiovascular disease and its preparing method
CN1634241A (en) Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process
CN101066327A (en) Functional health wine and its prepn process
CN1895346A (en) Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method
CN1883654A (en) Pulse invigorating injection with astragalus root and preparation process thereof
CN1593574A (en) Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process
CN1939389A (en) Chinese-medicinal preparation and its making method
CN1253198C (en) Medicinal composition for treating coronary heart disease and angina pectoris
CN1915250A (en) Medicinal composition, preparation method and quality control method
CN1541653A (en) Kudzu vine capsule for regulating blood pressure and blood fat, its preparation process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20060503

CX01 Expiry of patent term